Eli Lilly and Company $LLY Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

Key Points

• Connor Clark & Lunn increased its Eli Lilly stake by 16.6% to 49,070 shares (worth $37.44M) in Q3, and overall institutional ownership is about 82.5% as several other funds also added positions.
• Regulatory and commercial catalysts — including CMS expanding Medicare access to Zepbound and Mounjaro and a multibillion manufacturing build‑out in China plus additional Asian capacity investments — should boost near‑term demand and support global GLP‑1 rollout.
• Financial snapshot: Lilly beat the quarter with $7.54 EPS and revenue up 42.6%, set FY2026 guidance of 33.5–35.0 EPS, and trades below some short‑term moving averages while analysts’ consensus target is roughly $1,230.

Connor Clark & Lunn Investment Management Ltd. increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,070 shares of the company's stock after buying an additional 6,997 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in Eli Lilly and Company were worth $37,440,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in LLY. Exencial Wealth Advisors LLC boosted its stake in Eli Lilly and Company by 189.6% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock valued at $13,283,000 after purchasing an additional 11,396 shares in the last quarter. Rede Wealth LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth $487,000. Central Pacific Bank Trust Division lifted its holdings in shares of Eli Lilly and Company by 25.8% in the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company's stock valued at $6,859,000 after buying an additional 1,843 shares during the period. Cidel Asset Management Inc. boosted its stake in Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock valued at $20,392,000 after buying an additional 5,591 shares in the last quarter. Finally, Oak Family Advisors LLC bought a new position in Eli Lilly and Company during the third quarter valued at about $1,979,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Medicare access is expanding for Zepbound and Mounjaro, which should boost near‑term demand and reduce payer uncertainty for a large patient cohort. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Lilly announced a multibillion manufacturing build‑out in China to secure supply and capture a huge GLP‑1 market — a strategic long‑term revenue driver. Lilly to Invest $3 Billion in China to Boost Obesity Pill
• Positive Sentiment: Lilly is expanding manufacturing and partnerships in Asia (Korea $500M incubator and Japan plant expansion), diversifying capacity and helping global rollout. Eli Lilly invests $500 million in Korea's biotech growth
• Positive Sentiment: Lilly is pushing multiple product catalysts: an orforglipron filing/launch (oral GLP‑1) and follow‑on candidates (retatrutide) that can sustain growth beyond current injectables. Will Policy Shifts Accelerate Demand for Eli Lilly's GLP‑1 Drugs?
• Positive Sentiment: Employer Connect and LillyDirect initiatives aim to expand coverage and patient access (potential volume growth even if pricing is pressured). Lilly Employer Connect platform launch
• Neutral Sentiment: Premium share price and 5‑year outperformance have reignited stock‑split and megatrend commentary — sentiment boosters but not immediate fundamentals. Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years (LLY)
• Negative Sentiment: Lilly issued warnings after detecting an unknown impurity in compounded tirzepatide mixed with vitamin B12 — a safety/regulatory concern that can drive near‑term caution and compounding‑market scrutiny. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Shorter‑term technical/market‑sentiment concerns: some analysts/public pieces argue trading momentum has cooled since late 2025, which can accelerate sell‑offs after recent gains. Eli Lilly Reaching For Peak GLP‑1 Euphoria: Rotten Trading Momentum Since November
• Negative Sentiment: Lilly warned some Medicare plans or basic Part D designs might still leave patients with >$50 out‑of‑pocket costs under new CMS rules — a potential near‑term headwind to access and PR. Lilly Warns Some Medicare GLP‑1 Costs Could Exceed $50

Eli Lilly and Company Trading Down 2.2%

Shares of LLY opened at $977.47 on Friday. The business's 50-day moving average price is $1,039.17 and its 200 day moving average price is $947.29. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The stock has a market capitalization of $923.54 billion, a P/E ratio of 42.59, a P/E/G ratio of 1.16 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts' consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same period in the prior year, the firm earned $5.32 earnings per share. The business's quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. TD Cowen boosted their price target on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a "buy" rating in a research report on Thursday, January 29th. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. Rothschild & Co Redburn boosted their target price on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the stock a "neutral" rating in a report on Monday, January 26th. HSBC reissued a "hold" rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Finally, Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an "outperform" rating in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,229.59.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.